PepMLM generates binders to challenging therapeutic targets across cancer and neurological disease using protein sequence and ...

Schrödinger has halted development of its cancer-fighting candidate SGR-2921 after two patients treated with the CDC7 inhibitor died in a Phase I trial.

Researchers demonstrate that an engineered antibody improves a class of drugs that has struggled to make good on its early promise.

Peptidoglycan hydrolases killed living bacteria, opening the door for further research into the interplay between archaea and bacteria.

Researchers say work lays the foundation for a first-line, deployable antiviral platform that is virus agnostic and modular.